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Abstract
Aims: Treatment advances have improved cancer-related outcomes and shifted interest towards minimising long-term iatrogenic complications, particularly
chemotherapy-related cardiotoxicity. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of plasma troponin and
enable early detection of cardiomyocyte injury prior to the development of myocardial dysfunction. The profile of hs-cTnI in response to anthracycline-based
treatment has not previously been described.
Materials and methods: This was a multicentre prospective observational cohort study. Female patients with newly diagnosed invasive breast cancer scheduled
to receive anthracycline-based (epirubicin) chemotherapy were recruited. Blood sampling was carried out before and 24 h after each cycle. Hs-cTnI concen-
trations were measured using the Abbott ARCHITECTSTAT assay.
Results: We recruited 78 womenwith a median (interquartile range) age of 52 (49e61) years. The median baseline troponin concentration was 1 (1e4) ng/l and
the median cumulative epirubicin dose was 394 (300e405) mg/m2. Following an initial 33% fall 24 h after anthracycline dosing (P < 0.001), hs-cTnI con-
centrations increased by a median of 50% (P < 0.001) with each successive treatment cycle. In total, 45 patients had troponin measured immediately before the
sixth treatment cycle, 21 (46.6%) of whom had hs-cTnI concentrations 16 ng/l, indicating myocardial injury. Plasma hs-cTnI concentrations before the second
treatment cycle were a strong predictor of subsequent myocardial injury.
Conclusions: Cardiotoxicity arising from anthracycline therapy is detectable in the earliest stages of breast cancer treatment and is cumulative with each
treatment cycle. This injury is most reliably determined from blood sampling carried out before rather than after each treatment cycle.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
Key words: Anthracycline; breast cancer; cardiotoxicity; high-sensitivity cardiac troponin; left ventricular ejection fractionAuthor for correspondence: E. Tzolos, BHF Centre for Cardiovascular
Sciences, Queen's Medical Research Institute, 47 Little France Crescent,
Edinburgh, EH16 4TJ, UK. Tel: þ44 131 537 3834.
E-mail address: e.tzolos@ed.ac.uk (E. Tzolos).
* Authors contributed equally to this work.
https://doi.org/10.1016/j.clon.2019.11.008
0936-6555/ 2019 The Royal College of Radiologists. Published by Elsevier Ltd. Th
org/licenses/by/4.0/).
Please cite this article as: Tzolos E et al., Dynamic Changes in High-
Chemotherapy, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.11.0Introduction
Anthracyclines are associated with cardiotoxicity and the
development of heart failure [1]. The incidence of conges-
tive heart failure during doxorubicin treatment in three
studies comprising 630 breast and lung cancer patients rose
exponentially from 5% with a cumulative dose of 400 mg/
m2 to 48% with 700 mg/m2 [2]. With contemporary loweris is an open access article under the CC BY license (http://creativecommons.
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evidence of heart failure. For example, a study of car-
diotoxicity in 2625 patients (74% women; 51% breast cancer
and 28% non-Hodgkin lymphoma) reported lower rates of
symptomatic heart failure [3]. Cardiotoxicity was defined as
>10 percentage point decline in left ventricular ejection
fraction (LVEF) and a drop to <50%. The incidence of car-
diotoxicity was 9%, with 98% of cases developing in the first
year. In 82% of cases the cardiotoxicity was either asymp-
tomatic or only mildly symptomatic [3]. The recent PRADA
Study (Prevention of cardiac dysfunction during an Adju-
vant Breast Cancer Therapy) investigated breast cancer
patients receiving anthracycline and trastuzumab. In
PRADA, no patients developed symptomatic heart failure
and the mean drop in cardiac ejection fraction was only 2.6
percentage points [4].
The development of asymptomatic myocardial dysfunc-
tion has important implications with regards to cancer
treatment options [3,4]. Currently, the detection of cardiac
toxicity focusses on cardiac imaging, including quantifica-
tion of the LVEF [5]. This approach is operator dependent,
expensive and inefficient, as most patients are not affected
and receive unnecessary scans. Cardiac imaging is also
relatively insensitive to early toxicity and identifies only
advanced myocardial injury once changes in systolic or
diastolic function have occurred. Early recognition of car-
diac toxicity may allow targeted intervention in high-risk
individuals before clinically significant deterioration in
cardiac function. Although there are monitoring guidelines
for cardiotoxicity, the optimal timing for the early detection
of subclinical cardiotoxicity is still ambiguous [5,6].
Cardiac troponin I and T are specific markers of car-
diomyocyte injury. Previous studies using contemporary
sensitivity assays have shown a relationship between
troponin rise during and after anthracycline chemotherapy
and the subsequent development of left ventricular
dysfunction [7e9]. Patients with no troponin concentration
increase during or after chemotherapy are in a low-risk
group for the development of cardiotoxicity [7,10].
The development of high-sensitivity cardiac troponin
(hs-cTn) assays has allowed the accurate quantification of
very low concentrations and the detection of circulating
levels in over 50% of the healthy population [11,12]. Our
group has shown the powerful predictive value of small
changes in plasma hs-cTnI in a range of conditions affecting
the heart, including coronary heart disease [12e14], aortic
valve disease [15] and chronic obstructive airways disease
[16]. To date, few studies have examined hs-cTn measure-
ment in patients receiving anthracycline chemotherapy. In
the PRADA study, hs-cTnI and hs-cTnT concentrations
exhibited an anthracycline dose-dependent increase from
baseline, after the completion of chemotherapy [4,17].
Given the low-level troponin concentration increases that
occur after anthracycline administration, hs-cTn testing
may better inform risk stratification for the development of
left ventricular dysfunction. Furthermore, improved un-
derstanding of the kinetics of hs-cTn release and optimal
timing for blood sampling during anthracyclinePlease cite this article as: Tzolos E et al., Dynamic Changes in High-
Chemotherapy, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.11.0chemotherapy will allow the implementation of surveil-
lance protocols for cardiotoxicity.
The aim of this current study was to characterise the
change in plasma hs-cTnI concentration in patients with
breast cancer receiving anthracycline chemotherapy. This
work was carried out to inform the protocol of the ongoing
Cardiac CARE study (ISCRTN24439460), a randomised
multicentre study using hs-cTnI to identify cancer patients
at high risk of developing anthracycline cardiotoxicity.Materials and Methods
Study Design and Participants
Between January 2016 and August 2017, consecutive
patients with newly diagnosed breast cancer scheduled
for anthracycline treatment in the Edinburgh Cancer
Centre and the Beatson West of Scotland Cancer Centre
(Glasgow) were approached to take part. All patients had
a baseline LVEF >50% on echocardiography or radio-
nucleotide ventriculography. Patients were planned to
receive adjuvant chemotherapy with the FEC 80 regimen
(six cycles of 5-fluorouracil, epirubicin 80 mg/m2 and
cyclophosphamide) or adjuvant/neoadjuvant chemo-
therapy FEC 100 (three cycles of 5-fluorouracil, epirubicin
100 mg/m2 and cyclophosphamide) administered intra-
venously over 21-day cycles. FEC 100 was typically fol-
lowed by docetaxel or paclitaxel with or without
trastuzumab depending on HER2 status. However,
troponin results are only reported for the anthracycline-
containing cycles of treatment.
We measured hs-cTnI concentration at baseline (24 h
before cycle 1), during (24 h after anthracycline infusion)
and before each treatment cycle.
A high-sensitivity assay (ARCHITECTSTAT, Abbott Labora-
tories) was used to measure cardiac troponin I concentra-
tions. This assay has a limit of detection of 1.2 ng/l and an
upper reference limit (99th centile) of 34 ng/l in men and 16
ng/l in women. It has a coefficient of variation of 23% at the
limit of detection (1.2 ng/l) and <10% at 4.7 ng/l [11,12].
All statistical analyses, including correlation and non-
linear regression, were carried out with GraphPad Prism
version 8.0.1 (GraphPad Software, San Diego, California,
USA). P-value was calculated using one-way ANOVA.
All participants provided informed consent before
participation in the study.Results
We enrolled 78 women (median age 52 years, inter-
quartile range [IQR] 49e61 years) with low rates of car-
diovascular risk factors (Table 1).
The median troponin concentration before cycle 1 was 1
ng/l (IQR 1e4 ng/l). Pre-treatment hs-cTnI concentrations
increased with each cycle andwere strongly correlated withSensitivity Cardiac Troponin I in Response to Anthracycline-Based
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Table 1
Baseline characteristics
Total cohort
n 78
Age (years) 52 [49e61]
Body mass index (kg/m2) 28.2  5.7
Hypertension 17 (16)
Smoking habit
Current smoker 13 (13)
Ex-smoker 31 (30)
Never smoked 60 (58)
Diabetes mellitus 6 (6)
Baseline LVEF (%) 63.9  6.8
Baseline hs-cTnI (ng/l) 1.0 [1.0, 4.0]
Cumulative epirubicin dose (mg/m2) 394.1 [299.7, 405.4]
Hs-cTnI, high-sensitivity cardiac troponin I; LVEF, left ventricular
ejection fraction.
Data are mean  standard deviation, median [interquartile range]
or value (%).
E. Tzolos et al. / Clinical Oncology xxx (xxxx) xxx 3the cumulative epirubicin dose (r2 ¼ 0.9036; P ¼ 0.036)
(Figure 1).
Forty-five patients receiving the FEC 80 regimen had hs-
cTnI quantification before the sixth cycle and this groupwas
divided into tertiles according to hs-cTnI concentration
before the sixth epirubicin cycle (Figure 2). Baseline char-
acteristics, including troponin concentration 1 (1e4) ng/l,
were similar across tertiles of hs-cTnI, including age, body
surface area, LVEF, smoking status or an existing diagnosis
of diabetes or hypertension (P > 0.05 for all). Patients in the
highest tertile had a median (IQR) hs-cTnI concentration of
28 (24e35) ng/l before cycle 6 compared with 14 (12e20)
and 6 (5e8) ng/l for the middle and lowest tertiles,
respectively. There were no presentations of cardiac failure
in this cohort during chemotherapy.
Hs-cTnI concentration before the second treatment cycle
was a strong predictor of subsequent myocardial injury
(Figure 3). A threshold of 5 ng/l predicted subsequent
development of troponin concentrations in the highest
tertile before cycle 6, with a sensitivity of 69% and aFig 1. Correlation between circulating high-sensitivity cardiac
troponin I (hs-cTnI) concentration and cumulative epirubicin dose.
Scatterplot of individual patient hs-cTnI concentrations according to
cumulative epirubicin dose (n ¼ 78).
Please cite this article as: Tzolos E et al., Dynamic Changes in High-
Chemotherapy, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.11.0specificity of 86% (c-statistic¼ 0.80; 95% confidence interval
0.64e0.96).
Compared with before chemotherapy, hs-cTnI concen-
trations fell by 33% (P < 0.001) 24 h after chemotherapy
(Figure 4).Discussion
We have for the first time characterised the dynamic
increase in hs-cTnI concentration occurring during anthra-
cycline chemotherapy for breast cancer. Hs-cTnI assays are
extremely sensitive, allowing for earlier and faster recog-
nition of cardiotoxicity, offering clinicians a path to more
rapidly implement cardioprotective treatment. The new
assays are also precise, having small coefficient of variance
levels below the 99% upper reference limit and a lower
detection threshold when compared with contemporary
assays [18].
Plasma hs-cTnI concentrations showed an anthracycline
dose-dependent increase in accordance with the results of
the PRADA study that used limited blood sampling before
and after the completion of chemotherapy [17]. Using the
same assay, the PRADA investigators showed linear corre-
lation between baseline and post-chemotherapy hs-cTnI
concentrations. For patients receiving 400 mg/m2 cumula-
tive dose epirubicin, hs-cTnI rose from a median (IQR) of 1
ng/l (1e1.5) at baseline to 8 ng/l (4e14). Post-treatment hs-
cTnI concentrations were significantly lower in patients
receiving <400 mg/m2 cumulative dose. We quantified hs-
cTnI concentrations before and 24 h after each anthracy-
cline treatment to create a profile and identify the most
suitable time of blood sampling during treatment. Unlike
PRADA, our study was purely observational. By quantifying
hs-cTnI concentrations before the next cycle of anthracy-
cline chemotherapy wewere able to identify an exponential
increase for patients in the upper tertile with a median
(IQR) hs-cTnI concentration of 28 (24e35) ng/l.
More than a third of patients developed biochemical
evidence of sustained myocardial injury with plasma
troponin concentrations above the 99th centile upper
reference limit. Early changes in troponin accurately pre-
dicted final concentrations at the end of chemotherapy,
suggesting that hs-cTnI represents a patient-specific
marker anthracycline induced cardiotoxicity. By detecting
myocardial injury after only a single treatment dose,
troponin monitoring may allow early initiation of car-
dioprotective treatment in patients at greatest risk of
cardiotoxicity.
Although it is notable that patients in the upper tertile
exhibit a more obvious exponential troponin release, pa-
tients in the middle and lower tertiles also showed a degree
of myocardial injury, albeit to a lesser extent. This first
detailed profile of hs-cTnI concentrations supports the hy-
pothesis that although there is substantial interindividual
variation in sensitivity to the cardiotoxic effects of anthra-
cycline therapy, this is not an idiosyncratic reaction.
Our observation that hs-cTnI concentrations fell 24 h
after anthracycline administration was unexpected andSensitivity Cardiac Troponin I in Response to Anthracycline-Based
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Fig 2. High-sensitivity cardiac troponin I (Hs-cTnI) concentration tertile plot for patients receiving six cycles of epirubicin. Plot of hs-cTnI
concentration (median and interquartile range) tertiles according to concentration before sixth treatment cycle. The same patients in each
tertile from this final cycle are plotted in preceding cycles (n ¼ 45).
E. Tzolos et al. / Clinical Oncology xxx (xxxx) xxx4suggests that myocardial injury is reliably determined from
blood sampling carried out before rather than immediately
after each treatment cycle. The mechanism explaining this
early fall in hs-cTnI concentrations is uncertain but may be
related to concurrent treatments including intravenous
hydration and steroids administered with anthracycline
during chemotherapy. Although this hypothesis remains to
be tested, it illustrates the importance of understanding the
kinetics of circulating troponin concentrations when
selecting timepoints for monitoring cardiotoxicity.Fig 3. Receiver operator characteristics curve for the prediction of
cardiac troponin I concentrations in T3 (upper tertile) before the sixth
cycle, applying a threshold of 5 ng/l before cycle 2. AUC, area under
the curve; CI, confidence interval; NPV, negative predictive value;
PPV, positive predictive value.
Please cite this article as: Tzolos E et al., Dynamic Changes in High-
Chemotherapy, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.11.0In the absence of follow-up cardiac imaging, we were
unable to assess the correlation between increasing
troponin concentrations following anthracycline therapy
and changes in cardiac function on serial imaging. Similarly,
this study was underpowered to determine an association
between troponin concentrations and clinical events,
including death and heart failure. Nevertheless, the asso-
ciation between increased troponin concentrations and
both left ventricular function and cardiovascular events has
been well described in other contexts [19e21]. De Lemos
et al. [19] categorised 3546 participants aged 30e65 years in
a population-based cohort study according to hs-cTnT
concentrations. The prevalence of left ventricular dysfunc-
tion (LVEF < 40%) increased from 0.005% in the lowest hs-
cTnT category (<0.003 ng/ml) to 5.1% in the highest
(0.014 ng/ml) (P < 0.001). During a median follow-up of
6.4 years, there were 151 total deaths, including 62 car-
diovascular disease deaths. All-cause mortality increased
from 1.9% to 28.4% across higher hs-cTnT categories
(P< 0.001) [19]. After adjustment for traditional risk factors,
hs-cTnT concentration remained independently associated
with all-cause mortality (adjusted hazard ratio 2.8, 95%
confidence interval 1.4e5.2 in the highest category). Cardiac
troponin I concentrations predict the development of left
ventricular dysfunction and congestive cardiac failure in
patients receiving anthracycline containing high-dose
chemotherapy. Using a contemporary assay with a detec-
tion threshold of 80 ng/l, Cardinale et al. [7] showed that
patients with elevated concentrations during and after
chemotherapy had much higher rates of heart failure and
left ventricular dysfunction. After 3 years of follow-up, only
0.1% of patients with no cardiac troponin I concentration
increase developed heart failure compared with 44% of
patients exhibiting increased concentrations during and
after chemotherapy [7].Sensitivity Cardiac Troponin I in Response to Anthracycline-Based
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Fig 4. High-sensitivity cardiac troponin I (Hs-cTnI) concentration measured before and 24 h after each treatment cycle.
E. Tzolos et al. / Clinical Oncology xxx (xxxx) xxx 5Hs-cTnI may represent a better monitoring method
compared with imaging measures of LVEF or myocardial
strain, being relatively inexpensive, easier to perform, more
sensitive and capable of detecting early subclinical cardiac
injury.
In the oncology setting, previous studies with contem-
porary (non-high sensitivity) assays have shown the pre-
dictive value of elevated troponin concentrations for
cardiotoxicity and its potential as a marker to identify high-
risk patients warranting cardioprotective therapies [9,22].
Clinical trials investigating intervention and preventive
strategies in anthracycline cardiotoxicity are challenging
because the proportion of patients developing clinically
relevant cardiac dysfunction is small. We believe subtle
changes in troponin concentrations detected with high-
sensitivity assay testing will identify high-risk patients
early on during anthracycline treatment. This will identify a
patient group in need of closer monitoring. This is partic-
ularly important if additional cardiotoxic treatment, such as
trastuzumab, is planned. This approach is being adopted in
the ongoing UK Cardiac CARE study randomising high-risk
patients receiving anthracycline for breast and non-
Hodgkin lymphoma to cardioprotective therapy.
Cardiac CARE participants will have hs-cTnI concentra-
tions monitored before each cycle of chemotherapy. Pa-
tients with increased myocardial injury exhibiting upper
tertile hs-cTnI concentrations will be randomly allocated to
treatment with either a combination of angiotensin recep-
tor blocker and B-blocker or standard care. The primary end
point is change in LVEF on cardiac magnetic resonance
imaging 6 months after the completion of chemotherapy.Conflicts of Interest
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